האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamíð - flogaveiki - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - sýklalyf - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

האיחוד האירופי - איסלנדית - EMA (European Medicines Agency)

bial - portela ca, s.a. - eslikarbazepín asetat - flogaveiki - antiepileptics, - exalief er ætlað til viðbótarmeðferðar hjá fullorðnum með flogaveiki með eða án aukakvilla.

איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 100 mg

איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 200 mg

איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 25 mg

איסלנד - איסלנדית - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 50 mg